Find Out if You Qualify for a Financial Reward by filling out the form below.
Investigation Details
Chemours issued a press release on August 1, 2024, reporting its financial results for the second quarter of 2024. Among other items, Chemours reported non-GAAP earnings per share of $0.38, missing consensus estimates by $0.20. The Company advised that it “anticipates a low to mid-single digit sequential decline in Net Sales for the third quarter,” citing “[r]esidual impacts from Q2 unplanned downtime at our Altamira, Mexico manufacturing site” in its Titanium Technologies segment; “[r]efrigerant seasonality paired with weaker Freon™ Refrigerants pricing in its Thermal & Specialized Solutions segment; and “[a] continued modest recovery in” its Advanced Performance Materials segment.
Following this news, Chemours’s stock price dropped over 11% on August 2, 2024.
Ticker Symbol | Company Name | Join Deadline | Join |
---|---|---|---|
APLT | Applied Therapeutics, Inc. | February 18, 2025 | Join |
BIOA | BioAge Labs, Inc. | March 10, 2025 | Join |
PCRX | Pacira BioSciences, Inc. | March 14, 2025 | Join |
NVO | Novo Nordisk A/S | March 25, 2025 | Join |
GO | Grocery Outlet Holding Corp. | March 31, 2025 | Join |
NEM | Newmont Corporation | April 01, 2025 | Join |
GSK | GSK plc | April 07, 2025 | Join |
NTLA | Intellia Therapeutics, Inc. | April 14, 2025 | Join |
MRK | Merck & Co., Inc. | April 14, 2025 | Join |